'Sakigake' Treatment Gives Enhertu Rapid Japan OK For Gastric Cancer
Zejula, Tecentriq Combo Also Cleared
Executive Summary
Japan approves a batch of new products and indications, including Daiichi Sankyo's Enhertu in a high-need indication after a rapid review and Takeda's Zejula, which will be made available to selected patients before its reimbursement listing.
You may also be interested in...
China’s First ADC Secures Domestic Approval
RemeGen’s second approval after a green light for its lupus drug signals accelerating approvals for domestically-developed antibodies in China.
China’s First ADC Secures Domestic Approval
RemeGen’s second approval after a green light for its lupus drug signals accelerating approvals for domestically-developed antibodies in China.
Japan Regulators Kept On Track Despite Pandemic
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.